1.54

0.00% +0.00

After Hours: 1.53 -0.01 -0.65%

Geovax Labs Inc (GOVX)

Overview News Price History Discussions Forecast Stock Split

Geovax Labs Inc stock is currently priced at $1.54, with a 24-hour trading volume of 34,763. It has seen a +0.00% increased in the last 24 hours and a -21.83% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.59 pivot point. If it approaches the $1.49 support level, significant changes may occur.

Previous Close:

$1.54

Open:

$1.64

24h Volume:

34,763

Market Cap:

$3.55M

Revenue:

$356.60K

Net Income/Loss:

$-25.97M

P/E Ratio:

-2.0688

EPS:

-0.7444

Net Cash Flow:

$-25.22M

1W Performance:

+5.48%

1M Performance:

-21.83%

6M Performance:

+201.72%

1Y Performance:

+142.06%

1D Range:

$1.48

$1.6499

52W Range:

$0.25

$4.33

Geovax Labs Inc Stock (GOVX) Company Profile

Name

Geovax Labs Inc

Sector

Healthcare (1198)

Industry

Biotechnology (688)

Phone

678 384 7220

Address

1900 Lake Park Drive, Suite 380, Smyrna

Employee

Twitter

Next Earnings Date

2024-05-23

Latest SEC Filings

GOVX's Discussions on Twitter

Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-19-20	Initiated	Maxim Group	Buy

Geovax Labs Inc Stock (GOVX) Latest News

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

GlobeNewswire Inc.

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

GlobeNewswire Inc.

Geovax Labs Inc Stock (GOVX) Financials Data

Geovax Labs Inc (GOVX) Revenue 2024

GOVX reported a revenue (TTM) of $356.60 thousand for the quarter ending March 31, 2022, a -70.72% decline year-over-year.

Geovax Labs Inc (GOVX) Net Income 2024

GOVX net income (TTM) was -$25.97 million for the quarter ending December 31, 2023, a -85.20% decrease year-over-year.

Geovax Labs Inc (GOVX) Cash Flow 2024

GOVX recorded a free cash flow (TTM) of -$25.22 million for the quarter ending December 31, 2023, a -31.61% decrease year-over-year.

Geovax Labs Inc (GOVX) Earnings per Share 2024

GOVX earnings per share (TTM) was -$14.29 for the quarter ending December 31, 2023, a -6.51% decline year-over-year.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; EmVenio Research; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.